NASDAQ:BBIO - BridgeBio Pharma Stock Price, News, & Analysis

+1.51 (+5.81 %)
(As of 07/19/2019 04:00 PM ET)
Today's Range
Now: $27.51
50-Day Range N/A
52-Week Range
Now: $27.51
Volume298,653 shs
Average Volume683,353 shs
Market Capitalization$3.31 billion
P/E RatioN/A
Dividend YieldN/A
BridgeBio Pharma, Inc. finds, develops, and delivers various medicines for genetic diseases. The company has a pipeline of 15 development programs that include product candidates ranging from early discovery to late-stage development in various therapeutic areas, including genetic dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology. Its principal products in development programs include BBP-265, an oral small molecule transthyretin (TTR) for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers, as well as for the treatment of achondroplasia; BBP-631, a preclinical adeno-associated virus gene transfer product candidate for the treatment of congenital adrenal hyperplasia caused by 21OHD; and BBP-454, a preclinical development program for small molecule inhibitors of KRAS for the treatment of pan-mutant KRAS-driven cancers. The company was founded in 2015 and is headquartered in Palo Alto, California.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:BBIO



Sales & Book Value

Annual SalesN/A



Market Cap$3.31 billion
Next Earnings DateN/A
OptionableNot Optionable

Receive BBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter.

BridgeBio Pharma (NASDAQ:BBIO) Frequently Asked Questions

What is BridgeBio Pharma's stock symbol?

BridgeBio Pharma trades on the NASDAQ under the ticker symbol "BBIO."

Has BridgeBio Pharma been receiving favorable news coverage?

News coverage about BBIO stock has trended positive this week, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. BridgeBio Pharma earned a coverage optimism score of 2.1 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an impact on the stock's share price in the next several days. View News Stories for BridgeBio Pharma.

Who are some of BridgeBio Pharma's key competitors?

What other stocks do shareholders of BridgeBio Pharma own?

Who are BridgeBio Pharma's key executives?

BridgeBio Pharma's management team includes the folowing people:
  • Dr. Neil Kumar, Co-Founder, CEO & Director (Age 40)
  • Dr. Brian C. Stephenson, Chief Financial Officer (Age 38)
  • Dr. Uma Sinha, Chief Scientific Officer (Age 62)
  • Dr. Cameron Turtle, Sr. VP of Portfolio Management & Corp. Devel. (Age 29)
  • Dr. Charles J. Homcy, Chairman of Pharmaceuticals & Director (Age 71)

When did BridgeBio Pharma IPO?

(BBIO) raised $225 million in an initial public offering (IPO) on Thursday, June 27th 2019. The company issued 15,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, Jefferies, SVB Leerink and KKR served as the underwriters for the IPO and Piper Jaffray, Mizuho Securities, BMO Capital Markets and Raymond James were co-managers.

When does the company's quiet period expire?

BridgeBio Pharma's quiet period expires on Tuesday, August 6th. BridgeBio Pharma had issued 20,500,000 shares in its public offering on June 27th. The total size of the offering was $348,500,000 based on an initial share price of $17.00. During the company's quiet period, insiders and any underwriters involved in the IPO are prevented from issuing any research reports for the company because of SEC regulations. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

How do I buy shares of BridgeBio Pharma?

Shares of BBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BridgeBio Pharma's stock price today?

One share of BBIO stock can currently be purchased for approximately $27.51.

How big of a company is BridgeBio Pharma?

BridgeBio Pharma has a market capitalization of $3.31 billion. BridgeBio Pharma employs 152 workers across the globe.View Additional Information About BridgeBio Pharma.

What is BridgeBio Pharma's official website?

The official website for BridgeBio Pharma is

How can I contact BridgeBio Pharma?

BridgeBio Pharma's mailing address is 421 KIPLING STREET, PALO ALTO CA, 94301. The company can be reached via phone at 650-391-9740.

MarketBeat Community Rating for BridgeBio Pharma (NASDAQ BBIO)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  10 (Vote Outperform)
Underperform Votes:  10 (Vote Underperform)
Total Votes:  20
MarketBeat's community ratings are surveys of what our community members think about BridgeBio Pharma and other stocks. Vote "Outperform" if you believe BBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2019 by Staff

Featured Article: Leveraged Buyout (LBO)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel